Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia

Carly Oboudiyat*, Tamar Gefen, Eleni Varelas, Sandra Weintraub, Emily Rogalski, Eileen H. Bigio, M. Marsel Mesulam

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. Methods We retrospectively evaluated CSF amyloid β 1–42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. Results Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were “consistent with AD” had postmortem Alzheimer pathology. The two patients whose biomarker values were “not consistent with AD” had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. Discussion CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.

Original languageEnglish (US)
Pages (from-to)598-601
Number of pages4
JournalAlzheimer's and Dementia
Volume13
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Cerebrospinal Fluid
Dementia
Alzheimer Disease
Pathology
Amyloid
Biomarkers
Primary Progressive Aphasia
Progressive Supranuclear Palsy
Frontotemporal Dementia
Autopsy

Keywords

  • Atypical Alzheimer's disease
  • Behavioral variant frontotemporal dementia
  • Neuropathology
  • Primary progressive aphasia
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

@article{393badc5594448b385e890732c57fc7e,
title = "Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia",
abstract = "Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. Methods We retrospectively evaluated CSF amyloid β 1–42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. Results Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were “consistent with AD” had postmortem Alzheimer pathology. The two patients whose biomarker values were “not consistent with AD” had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. Discussion CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.",
keywords = "Atypical Alzheimer's disease, Behavioral variant frontotemporal dementia, Neuropathology, Primary progressive aphasia, Progressive supranuclear palsy",
author = "Carly Oboudiyat and Tamar Gefen and Eleni Varelas and Sandra Weintraub and Emily Rogalski and Bigio, {Eileen H.} and Mesulam, {M. Marsel}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.jalz.2017.01.006",
language = "English (US)",
volume = "13",
pages = "598--601",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "5",

}

Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia. / Oboudiyat, Carly; Gefen, Tamar; Varelas, Eleni; Weintraub, Sandra; Rogalski, Emily; Bigio, Eileen H.; Mesulam, M. Marsel.

In: Alzheimer's and Dementia, Vol. 13, No. 5, 01.05.2017, p. 598-601.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia

AU - Oboudiyat, Carly

AU - Gefen, Tamar

AU - Varelas, Eleni

AU - Weintraub, Sandra

AU - Rogalski, Emily

AU - Bigio, Eileen H.

AU - Mesulam, M. Marsel

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. Methods We retrospectively evaluated CSF amyloid β 1–42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. Results Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were “consistent with AD” had postmortem Alzheimer pathology. The two patients whose biomarker values were “not consistent with AD” had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. Discussion CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.

AB - Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. Methods We retrospectively evaluated CSF amyloid β 1–42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. Results Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were “consistent with AD” had postmortem Alzheimer pathology. The two patients whose biomarker values were “not consistent with AD” had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. Discussion CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.

KW - Atypical Alzheimer's disease

KW - Behavioral variant frontotemporal dementia

KW - Neuropathology

KW - Primary progressive aphasia

KW - Progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=85014196999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014196999&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.01.006

DO - 10.1016/j.jalz.2017.01.006

M3 - Article

C2 - 28196768

AN - SCOPUS:85014196999

VL - 13

SP - 598

EP - 601

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 5

ER -